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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
This review aims to look at the benefits and harms of azithromycin for the treatment of BOS in adult lung transplant recipients.
B A C K G R O U N D
Description of the condition
Lung transplantation is potentially the only life-prolonging treat-
ment available for end-stage chronic lung disease. However, de-
spite significant advances in recipient selection, surgical technique,
and immunosuppressant therapy, which have led to improvements
in survival, the median survival remains poorer than other solid
organ transplants at 5.7 years (ISHLT Report 2015). Bronchioli-
tis obliterans syndrome (BOS) is a major subtype of the recently
termed Chronic Lung Allograft Dysfunction (CLAD) or late graft
failure after lung transplantation. BOS is estimated to develop in
50% of adult lung transplant recipients within 5 years of trans-
plantation and in 76% by 10 years (ISHLT Report 2015), and
was the most common indication for adult lung re-transplanta-
tion during January 1995 to June 2013 (ISHLT Report 2014),
internationally.
As defined by the International Society for Heart and Lung Trans-
plantation (ISHLT) guidelines, BOS is a delayed allograft dysfunc-
tion, characterised by a persistent (more than three weeks) obstruc-
tive lung function with a decline in forced expiratory volume in
one second (FEV1), which is not caused by other known and po-
tentially reversible causes of post-transplant loss of lung function
(Meyer 2014). Obliterative bronchiolitis (OB) is the hallmark of
BOS on histopathology (Verleden 2014), although, it is difficult
to diagnose on transbronchial lung biopsy, the most commonly
used biopsy method in clinical practice. BOS is graded according
to the severity of FEV1 decline, as per the 2001 diagnostic criteria
(Estenne 2002):
• BOS 0: FEV1 > 90% of baseline and FEF25−75 > 75% of
baseline post transplant (FEF25−75 = forced expiratory flow at
25% to 75% of forced vital capacity)
• BOS 0-p: FEV1 81% to 90% of baseline and/or FEF25−75
≤ 75% of baseline
• BOS 1: FEV1 66% to 80% of baseline post-transplant
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FEV1
• BOS 2: FEV1 51% to 65% of baseline post-transplant
FEV1
• BOS 3: FEV1 50% or less of baseline post-transplant FEV1
There are twomainCLADphenotypes: classic BOS and restrictive
allograft syndrome (RAS). RAS is characterised by total lung ca-
pacity (TLC) ≤ 90% of stable baseline value, normal or increased
FEV1 to forced vital capacity (FVC) ratio (FEV1/FVC),with FEV1
and/or FVC decline ≤ 90% of stable baseline value, infiltrates
on high resolution computed tomography (HRCT) with/without
bronchiectasis and air trapping, and parenchymal or pleural fibro-
sis on biopsy with/without OB. RAS is progressive and may start/
coincide with BOS. Approximately 40% of patients with BOS
respond to azithromycin with an increase in their FEV1 of at least
10% after two to three months of treatment, and some patients
may experience complete reversal of their FEV1 decline and return
to BOS stage 0. This phenotype has been termed azithromycin-
responsive allograft dysfunction (ARAD) or azithromycin-respon-
sive BOS, which can only be diagnosed retrospectively after the de-
cline in FEV1 has been diagnosed, and has subsequently responded
to azithromycin. It is unclear whether ARADwill progress to BOS
eventually. BOS remains the physiologic surrogate for OB, and
the most common phenotype of obstructive CLAD (Kapila 2015;
Verleden 2014).
This review uses the term BOS as described in the 2001 diag-
nostic criteria, which is the criteria used in clinical studies, while
acknowledging that ARAD, as defined by Verleden 2014, poses
a retrospective challenge to the diagnostic pathway. We note that
there remains debate within the field. Whilst we use the 2001 di-
agnostic pathway for practical reasons, we note that, as the field
evolves, future versions of this review may use an updated diag-
nostic pathway.
Description of the intervention
Currently there is no gold standard treatment for BOS; this
has resulted in a range of therapies being tried, which have in-
cluded switching immunosuppressants, total lymphoid irradia-
tion (McKay 2014), and Nissen’s fundoplication in cases of gas-
tro-oesophageal reflux disease (Meyer 2014). Azithromycin is a
macrolide antibiotic, which was initially trialled for the treatment
of BOS in early 2000s (Gerhardt 2003; Verleden 2004), noting
the success of maintenance macrolide therapy in management of
Japanese panbronchiolitis (Hui 2013), asthma (Brusselle 2013),
and chronic obstructive pulmonary disease (COPD) (Albert
2011).
How the intervention might work
Azithromycin is currently hypothesised to primarily impact BOS
via its immunomodulatory and anti-inflammatory pathway (Vos
2012). BOS is a heterogeneous entity with a variable natural his-
tory. There are at least two distinct subsets, which are characterised
by neutrophilic or fibroproliferative phenotypes (Vanaudenaerde
2008). Patients with the neutrophilic subset of BOS may re-
spond to azithromycin, and have reduced bronchoalveolar lavage
neutrophil count following three to six months of azithromy-
cin maintenance therapy (Gottlieb 2008; Vanaudenaerde 2008;
Verleden 2006). Additionally, azithromycin reduces interleukin-8
levels (Verleden 2006) modulating the immune system. Further-
more, azithromycin may reduce airway inflammation by enhanc-
ing oesophageal motility and accelerating gastric emptying, reduc-
ing gastric content aspiration (an established risk factor for de-
volvement and progression of BOS) (Corris 2015; Mertens 2009;
Vos 2012).
Why it is important to do this review
BOS is the Achilles heel of lung transplantation; it is the major
cause of late graft failure after lung transplantation and mortal-
ity. Therapeutic approaches for BOS have ranged from switch-
ing immunosuppression to total lymphoid irradiation, which have
had variable and modest impact on the rate of decline in graft
function in BOS (Fisher 2005; Verleden 2009), but are often as-
sociated with significant iatrogenic complications, such as bone
marrow failure and death in the case of total lymphoid irradia-
tion (Diamond 1998). Maintenance low dose azithromycin, of-
ten administered orally three times/week, has been in use for over
a decade. It has a good safety profile, with cardiac dysrhythmias
(Albert 2014; Ray 2012) and hearing impairment (Mick 2007)
as the main complications. Furthermore, studies have reported
development of macrolide resistance with the prolonged use of
azithromycin (Hansen 2009; Pomares 2011), but it remains to
be seen whether this resistance is of clinical significance. There is
also concern that long-term use of azithromycin in patients with
nontuberculous mycobacteria infection could lead to resistance,
further complicating its treatment (Mogayzel 2013). There have
been a number of studies published, with results ranging from no
improvement in lung function (Porhownik 2008) to slowing the
progression of disease (Shitrit 2005) and improved life expectancy
(Jain 2010; Yates 2005).More recently, randomised controlled tri-
als (RCTs) have also been published that have investigated azithro-
mycin for either treatment of BOS or as a prophylaxis against de-
velopment of BOS (Corris 2015; Vos 2011). Therefore, in light
of the new evidence supporting the use of azithromycin in BOS
and the potential complication associated with its long-term use,
this Cochrane review aims to assess the efficacy of azithromycin
for treatment of BOS in adult lung transplant recipients.
O B J E C T I V E S
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This review aims to look at the benefits and harms of azithromycin
for the treatment of BOS in adult lung transplant recipients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment
was obtained by alternation, use of alternate medical records, date
of birth or other predictable methods) looking at azithromycin for
BOS in adult lung transplant recipients.
Types of participants
Adult lung transplant recipients, both male and female, who have
been diagnosed with BOS, as per 2001 criteria (Estenne 2002),
will be included.
Inclusion criteria
• Lung transplant recipients, including single lung, double
lung, re-do transplants, and heart and lung transplant recipients.
• Male and female patients.
• Age 18 years and over.
Exclusion criteria
• Lung transplant recipients under the 18 years of age will be
excluded as azithromycin has not been established for treatment
of BOS in the paediatric lung transplant recipient cohort.
Types of interventions
• We will compare the daily dosing regimen to three times a
week regimen.
• We will compare long term (eight weeks and more) oral





Azithromycin in capsule, tablet, and oral suspension formulation
is accepted. It is expected for the patients diagnosed with BOS to
receive high dose intravenous methylprednisolone followed by a
tapering course of oral steroids, and optimisation of immunosup-
pressant therapy, as standard treatment.
Types of outcome measures
Primary outcomes
1. Lung function improvement, defined as ≥ 10%
improvement in FEV1
2. Progression to BOS stage 3
Secondary outcomes
1. Absolute change in FEV1
2. Decision to re-transplant
3. Survival
4. All adverse events, including hearing impairment, cardiac
dysrhythmias, prolonged QT interval on ECG, and
hepatotoxicity.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Kidney and Transplant Specialised
Register through contact with the Information Specialist using
search terms relevant to this review. The Cochrane Kidney and
Transplant Specialised Register contains studies identified from
several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
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2. Letters seeking information about unpublished or
incomplete trials to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and
abstracts of studies thatmay be relevant to the review.The titles and
abstracts will be screened independently by two authors, who will
discard studies that are not applicable; however, studies and reviews
that might include relevant data or information on trials will be
retained initially. Two authors will independently assess retrieved
abstracts and, if necessary the full text, of these studies to determine
which studies satisfy the inclusion criteria. Any disagreements will
be resolved by discussion, and, if necessary, arbitration by the third
or fourth author.
Data extraction and management
Data extraction will be carried out independently by two authors
using standard data extraction forms. Studies reported in non-
English language journals will be translated before assessment.
Where more than one publication of one study exists, reports will
be grouped together and the publication with the most complete
data will be used in the analyses. Where relevant outcomes are
only published in earlier versions these data will be used. Any
discrepancy between published versions will be highlighted.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (reversal of BOS, halted progression
of BOS, progression to next BOS stage, re-transplantation, and
death) results will be expressed as risk ratio (RR) with 95% confi-
dence intervals (CI).Where continuous scales of measurement are
used to assess the effects of treatment (FEV1), the mean difference
(MD) will be used, or the standardised mean difference (SMD) if
different scales have been used.
Where death or re-transplantation are reported as a time to event
data, these will be analysed as per the Cochrane Handbook, using
summary statistics from individual trial reports. If estimates of log
hazard ratios and standard errors are available from Cox propor-
tional hazards are available, these will be analysed by the generic
inverse-variance method. If O-E and variance data, or if log rank
methods are reported, these will be analysed with Peto’s method.
If standard deviations of changes from baseline (such as for FEV1)
are missing, these will be calculated if other information (such as
P values) are available. If this is not possible, we will impute stan-
dard deviations using the methods from the Cochrane Handbook
Chapter 16.
Unit of analysis issues
For cross-over studies, where possible, we will use the first treat-
ment cycle prior to the ’cross-over’, to avoid the effect of treatment
’hangover’. Where multiple groups are investigated in one study,
we will use each group only once in meta-analysis, to remove the
impact of unit of analysis issues. Where possible, we will combine
groups to make a single pair-wise comparison. Other approaches
which will be taken are (i) removing interventions not relevant to
this review, (ii) splitting a shared group into multiple groups and
including these in the meta-analysis or (iii) including correlated
comparisons, and using appropriate methods for accounting with
the correlation.
Dealing with missing data
Any further information required from the original author will be
requested by written correspondence (e.g. emailing corresponding
authors) and any relevant information obtained in this manner
will be included in the review. Evaluation of important numerical
data such as screened, randomised patients as well as intention-
to-treat, as-treated and per-protocol population will be carefully
performed. Attrition rates, for example drop-outs, losses to follow-
up and withdrawals will be investigated. Issues of missing data
and imputation methods (for example, last-observation-carried-
forward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
We will first assess the heterogeneity by visual inspection of the
forest plot.Heterogeneitywill thenbe analysed using aChi2 test on
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N-1 degrees of freedom, with an alpha of 0.05 used for statistical
significance and with the I2 test (Higgins 2003). A guide to the
interpretation of I2 values will be as follows:
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity.
The importance of the observed value of I2 depends on the mag-
nitude and direction of treatment effects and the strength of evi-
dence for heterogeneity (e.g. P-value from the Chi2 test, or a CI
for I2) (Higgins 2011).
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of publication bias (Higgins 2011).
Data synthesis
Data will be pooled using the random-effects model but the fixed-
effect model will also be used to ensure robustness of the model
chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be used to explore possible sources of het-
erogeneity (e.g. studies with or without blinding). Heterogeneity
among participants could be related to the type of transplant (e.g.
single versus double versus heart-lung transplant). Heterogeneity
in treatments could be related to prior agent(s) used and the dose
and duration of therapy (e.g. azithromycin 250 mg versus 500
mg). Adverse effects will be tabulated and assessed with descrip-
tive techniques. Where possible, the risk difference with 95% CI
will be calculated for each adverse effect, either compared to no
treatment or to another agent.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country
• Repeating the analysis excluding quasi-RCTs.
’Summary of findings’ tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schunemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008). The GRADE approach defines the quality of a
body of evidence as the extent to which one can be confident that
an estimate of effect or association is close to the true quantity of
specific interest. The quality of a body of evidence involves consid-
eration of within-trial risk of bias (methodological quality), direct-
ness of evidence, heterogeneity, precision of effect estimates and
risk of publication bias (Schunemann 2011b). We plan to present
the following outcomes in the ’Summary of findings’ tables.
• Lung function improvement, defined as ≥ 10%
improvement in FEV1
• Proportion of patients progressing to BOS stage 3
• Decision to re-transplant
• Survival
• Adverse events, including hearing impairment, cardiac
dysrhythmias, prolonged QT interval on ECG, and
hepatotoxicity.
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Lung Transplantation] explode all trees
2. MeSH descriptor: [Organ Transplantation] this term only
3. lung transplant*:ti,ab,kw (Word variations have been searched)
4. {or #1-#3}
5. MeSH descriptor: [Bronchiolitis Obliterans] this term only
6. bronchiolitis obliterans or obliterative bronchiolit* or obliterating bronchiolit*:ti,ab,kw (Word variations have
been searched)
7. proliferative bronchioliti*:ti,ab,kw (Word variations have been searched)
8. constrictive bronchioliti*:ti,ab,kw (Word variations have been searched)
9. exudative bronchioliti*:ti,ab,kw (Word variations have been searched)
10. {or #5-#9}
11. MeSH descriptor: [Azithromycin] this term only
12. azithromycin:ti,ab,kw (Word variations have been searched)
13. sumamed:ti,ab,kw (Word variations have been searched)
14. toraseptol:ti,ab,kw (Word variations have been searched)
15. azadose:ti,ab,kw (Word variations have been searched)
16. ultreon:ti,ab,kw (Word variations have been searched)
17. vinzam:ti,ab,kw (Word variations have been searched)
18. zentavion:ti,ab,kw (Word variations have been searched)
19. zithromax:ti,ab,kw (Word variations have been searched)
20. zitromax:ti,ab,kw (Word variations have been searched)
21. {or #11-#20}
22. {and #4, #10, #21}
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Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimisation (minimisation may be imple-
mented without a random element, and this is considered to be
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(Continued)
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
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High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardised difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. sub-scales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
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tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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